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doi:10.1Objective: Left ventricular assist device (LVAD) implantation is an established option for treatment of patients
with end-stage heart failure, but outcomemay beworsened by right ventricular failure. The aim of this study was
to evaluate the acute effect of LVAD on right ventricular geometry and function and the pulmonary circulation.
The effect of inhaled nitric oxide (iNO) was assessed.
Methods: We evaluated pre- and postoperatively obtained transesophageal echocardiography images and
hemodynamics of patients participating in a randomized trial on the effect of inhaled nitric oxide during
LVAD implantation. Twenty-four patients were randomized to the iNO group and 23 to the placebo group.
Results:After LVAD implantation marked decreases in pulmonary capillary wedge pressure (P<.01) and mean
pulmonary artery pressure (P<.01) were observed in both groups. Pulmonary vascular resistance decreased only
in the iNO group (311  35 to 225 17, P<.01). Transesophageal echocardiography measurements show sig-
nificant improvement of right ventricular geometry (right ventricular end-diastolic diameter: 50  2 to 45  2,
P<.01 and 48  2 to 44 2 mm, P<.05 in iNO and placebo groups) and function (right ventricular fractional
area change: 24%  2% to 31%  2%, P<.05 and 23%  2% to 29%  2%, P<.05 in iNO and placebo
groups) without any difference between the iNO and placebo groups. The overall incidence of postoperative
right ventricular failure was 4 of 47 (8.5%).
Conclusions: LVAD implantation markedly improved right ventricular geometry and function in most of the
patients, probably by resolving left ventricular congestion and thus reducing right ventricular afterload. Bene-
ficial effects of iNO may have been masked by more pronounced consequences of left ventricular unloading on
right ventricular function. (J Thorac Cardiovasc Surg 2011;141:1009-14)P
MVentricular assist device is a well established and effective
therapy in patients with end-stage heart failure.1 Mechani-
cal support improves hemodynamics, organ function, qual-
ity of life, and survival. Isolated left ventricular assist device
(LVAD) implantation is preferred because of better quality
of life and better risk/benefit ratio.2
The main complication in these patients is right ventric-
ular failure (RVF), which is reported in 17% to 39% of
cases.3-8 RVF may result in compromised LVAD flow,
reduced tissue perfusion, and multiorgan dysfunction, all
of which are associated with a significant increase in
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The Journal of Thoracic and CarThe preoperative selection of patients for LVAD or biven-
tricular assist device (BiVAD) implantation is crucial and can
improve patient outcome. Diverse scoring systems have
been developed to predict RVF.4,6,8 In our institution,
patients are selected for LVAD implantation according to
tricuspid regurgitation, right ventricular (RV) geometry in
transthoracic echocardiography, and mean pulmonary
pressure,8 which results in an incidence of RVF after LVAD
implantation of about 10% to 12% (unpublished data).
The acute impact of LVAD on RV function in patients
with end stage heart failure (HF) is not well characterized.
Theoretically, the RV may benefit from a reduction of left
atrial pressure. On the other hand, leftward ventricular
septal shift and increased venous return induced by LVAD
is identified to impair RV function.9,10 Thus, the first aim
of this study was to characterize in detail the acute impact
of LVAD implantation on RV geometry and function and
on hemodynamics.
Patients with severe postoperative RV dysfunction re-
quire prolonged pharmacological support and in some cases
additional RV assist device implantation. Clinical outcome
of these patients is reported to be worse in comparison with
patients scheduled for primary BiVAD implantation.11diovascular Surgery c Volume 141, Number 4 1009
Abbreviations and Acronyms
BiVAD ¼ biventricular assist device
EF ¼ ejection fraction
FAC ¼ fractional area change
HF ¼ heart failure
iNO ¼ inhaled nitric oxide
LVAD ¼ left ventricular assist device
LVFRI ¼ left ventricular pump flow rate index
RVF ¼ right ventricular failure
RVOT ¼ right ventricular outflow tract
TAPSE ¼ tricuspid annular plane systolic
excursion
TEE ¼ transesophageal echocardiography
TPPG ¼ transpulmonary pressure gradient
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MPharmacological strategies can help to ameliorate RV dys-
function and to avoid the development ofRV failure. Conven-
tional intravenous drug therapies include catecholamines,
phosphodiesterase-III inhibitors, nitrates, and prostaglandins.
The intravenous administration of vasodilators to reduce RV
afterload is limited by inducing systemic vasodilatation and
concomitant low myocardial perfusion pressure.
Inhaled nitric oxide (iNO) has been shown to be of benefit
in the intraoperative management of patients with elevated
pulmonary vascular resistance undergoing heart transplan-
tation, lung transplantation, and other cardiac surgery.12-14
After LVAD implantation, iNO is frequently used
prophylactically during cardiopulmonary bypass weaning
to minimize the incidence and severity of postoperative
RV dysfunction.15-18 The clinical benefit of this strategy,
however, is still unclear. Thus, the second aim of the study
was to assess the effect of iNO on RV geometry and
function and on hemodynamics. To this effect, we
evaluated perioperatively-obtained transesophageal echo-
cardiography (TEE) images of patients participating in
a randomized, controlled, multicenter trial on the effect of
iNO on clinical outcome after LVAD implantation.MATERIALS AND METHODS
A prospective, randomized, double-blind, multicenter, placebo-
controlled trial was conducted at 8 centers in the United States and Ger-
many between September 2003 and March 2008. For the present study,
we included the Berlin subset of patients participating. The study was ap-
proved by the institutional ethics committee and all patients gave informed
written consent.
Patients over 18 years of age scheduled to undergo their first LVAD
placement were screened for enrollment. Patients with a pulmonary vascu-
lar resistance greater than 200 dyn 3 sec 3 cm5 before LVAD placement
were eligible for the trial. Patients received either iNO at a concentration of
40 ppm or placebo (an equivalent concentration of nitrogen), initiated at
least 5 minutes before the first weaning attempt from cardiopulmonary by-
pass (CPB) and continued until the patient: (1) was extubated; (2) devel-
oped RV failure; or (3) was treated for 48 hours, whichever came first.1010 The Journal of Thoracic and Cardiovascular SurPatients had the option to cross over to open-label iNO immediately and re-
main on iNO for up to 14 days, if they: (1) failed to wean at least once from
CPB due to hemodynamic failure, (2) still required pulmonary vasodilator
support at the 48-hour point, or (3) met the predefined RV failure criteria.
RV failurewas defined by the occurrence of two of the following criteria
in the absence of cardiac tamponade within the first 48 hours after surgery:
mean arterial pressure less than 55 mmHg; central venous pressure greater
than 16 mm Hg; mixed venous saturation less than 55%; cardiac index
greater than 2 L 3 min1 3 m2; inotropic support greater than 20 units.
The inotropic score was calculated as described previously.19
Blinded INOvent delivery systems (Ikaria, Clinton, NJ) were used for
this study.
The target of the hemodynamic management after CPB weaning was to
achieve a cardiac index of greater than 2 L3min13m2, a mixed venous
saturation greater than 55% and an appropriate balance between the RV
and supported LV to avoid excessive LV unloading and the resulting geo-
metrical disadvantage for the RV. Interventricular balance was monitored
by TEE and an end-diastolic middle position of the ventricular septum in
the 4-chamber view was considered optimum.Echocardiography
According to recommendations of the American Society of Echocardi-
ography (ASE), standard TEE views for assessment of LVand RV function
were acquired and digitally stored (Vivid 7,Vivid I; GE Vingmed Ultra-
sound, Horten, Norway) immediately preoperatively after induction of an-
esthesia and after skin suture, both during periods of hemodynamic steady
state.
To assess RV inflow tract we acquired the midesophageal 4-chamber
view (ME 4C). We changed the multiplane angle from approximately
0 to 20 to maximize the obtainable RV size. The RV outflow tract
(RVOT) was assessed from the midesophageal position in the RV inflow-
outflow view.
For LV geometric measurements we used the transgastric two-chamber
view (TG 2C) of the LV, usually best imaged at an angle of approximately
90 to 110 after optimizing for the maximum obtainable LV size.
A retrospective analysis of intraoperative echocardiographic data was
carried out by an experienced echo cardiographer who was blinded to out-
come parameters using an Echopac work station (Echopac, GE Vingmed
Ultrasound, Horten, Norway).
For assessment of RV geometry, RV function and LV geometry param-
eters recommended for chamber quantification by the ASE were used.20
To quantify RV size, basal (RVEDD 1), midcavity (RVEDD 2), and max-
imal (RVEDD max) short axis diameters at end-diastole were measured.
In addition, RV longitudinal diameter (RVEDD 3) was obtained. For
quantification of RVOT from the midesophageal RV inflow-outflow
view we measured the diameters at the subpulmonary region (RVOT 1)
and at the pulmonary valve annulus (RVOT 2). The end-diastolic and
end-systolic distances between the lateral tricuspid valve annulus and
the anterior annulus of the pulmonary valve were obtained for volume
calculation.21
For assessment of RV function the RV fractional area change from
end-diastolic and end-systolic areas measured in the ME 4C view was
calculated. Additional assessment of the RV systolic function included
measurement of tricuspid annular plane systolic excursion (TAPSE) from
ME 4C view using M-mode. For volumetric calculation of RV ejection
fraction a modified area length method was applied, using the areas from
ME 4C view and length from RV inflow outflow view.21
LV loading was quantified by the short-axis diameter at end diastole
(LVEDD) from the TG 2C view of the LV. The diameter was measured
from the endocardium of the inferior wall to the endocardium of the
anterior wall in a line perpendicular to the long axis of the ventricle at
the junction of the basal and middle thirds of the long axis. To assess the
interdependence between RVand LV the ratio of RVEDD max to LVEDD
(R/L ratio) was calculated.gery c April 2011
TABLE 2. Number and type of LVAD used in LVAD groups
Pump type Flow type iNO Placebo
Berlin Heart Incor Axial 16 15
HeartMate II Axial 6 7
DuraHeart Centrifugal 2
Ventrassist Centrifugal 1
Total 24 23
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Mean arterial pressure, mean pulmonary pressure, pulmonary arterial
wedge pressure, central venous pressure, and cardiac output weremeasured
after induction of anesthesia, after chest closure, and 6 hours postopera-
tively. Transpulmonary pressure gradient was calculated as mean pulmo-
nary pressure minus pulmonary arterial wedge pressure. Cardiac index
and pulmonary vascular resistance were calculated according to standard
formulae.iNO, Inhaled nitric oxide; LVAD, left ventricular assist device. Type of flow is indi-
cated.
Clinical Outcome
Although this study was not powered for clinical outcome, duration of
mechanical ventilation, intensive care unit (ICU) stay, 30-day mortality,
inotropic score, and the incidence of RV failure were assessed.
Statistical Analysis
The impact of LVAD implantation on echocardiographic and hemody-
namic variables and the additional effect of iNO were evaluated by two-
way repeated measures ANOVA followed by Holm-Sidak post-hoc tests.
Patient characteristics and outcome data were compared between groups
by Mann-Whitney rank sum test for continuous data and by Fisher’s exact
test for dichotomous data.RESULTS
Forty-seven patients received complete preoperative and
postoperative TEE exams and were included in the analysis.
Twenty-four patients were randomized to the iNO group.
Twenty-three patients were randomized to the placebo
group.
Table 1 shows the clinical characteristics of the patients.
There was no significant difference among groups with re-
gard to sex distribution, body mass index, origin of cardio-
myopathy, prevalence of mitral regurgitation, and right
ventricular pacing.
Table 2 shows the numbers and types of devices em-
ployed in patients. All LVADs were continuous-flow de-
vices. Most frequently implanted axial pumps included
Berlin Heart Incor (n ¼ 31, 7%) and HeartMate II
(n ¼ 13, 3%).P
MHemodynamic Data
Table 3 shows the hemodynamic changes immediately
and 6 hours after LVAD implantation in both groups. Pul-TABLE 1. Patient characteristics
iNO Placebo P
N 24 23
DCM/ICM 15/9 17/6 .53
Male/female 20/4 21/2 .67
Age (y) 56  10 53  13 .59
BMI (kg/m2) 27.5  4.2 26.5  4.2 .51
MI 1.4  0.9 1.4  0.8 .67
RV-pacing (%) 4 (17) 4 (17) 1.0
ICD (%) 12 (50) 11 (49) 1.0
BMI, Body mass index; DCM, dilatative cardiomyopathy; ICD, internal cardiac de-
fibrillator; ICM, ischemic cardiomyopathy; MI, mitral valve insufficiency classifica-
tion. Rates or means  standard deviation are given.
The Journal of Thoracic and Carmonary capillary wedge pressure and mean pulmonary ar-
tery pressure decreased markedly in both groups without
difference between iNO and placebo therapy. The transpul-
monary pressure gradient remained unchanged. Cardiac in-
dex improved significantly in both groups. Calculated
pulmonary vascular resistance decreased significantly in
the iNO group but not in placebo group. Central venous
pressure remained unchanged in both groups.Echocardiographic Data
Table 4 shows the echocardiography data describing RV
and LV geometry and RV function immediately before and
after LVAD implantation. Comparison of geometrical data
reveals acute improvement of RV end-diastolic geometry
by LVAD implantation via decreases in RVannular diameter
(RVEDD 1), maximal RV inflow diameter (RVEDD max),
RV long axis diameter (RVEDD 3), and RV end-diastolic
area. RV functional data show marked increases in frac-
tional area change (FAC) and ejection fraction (EF). There
was no significant difference between groups. RV func-
tional improvement as assessed by changes in FAC and
EF was most pronounced in patients with severely impaired
preoperative RF function (Figure 1).Clinical Outcome
In-hospital clinical outcome (Table 5) assessed as inotro-
pic equivalent index, ventilation in hours, ICU stay in days,
incidence of RV dysfunction and 30-day mortality shows no
difference between groups. Overall incidence of RV failure
was 8.5% (4/47).
Three patients in iNO group and one patient in placebo
group developing RVF presented with different clinical
problems. One feature common in all patients were larger
than average RV and smaller than average LV preopera-
tively (R/L ratios 0.97/0.94/0.91 and 0.74 to compare with
mean for all patients of 0.68).This higher R/L ratio may in-
dicate severe reduced RV function and disturbed ventricular
interdependence.
One patient presented preoperatively with the lowest CI
and the highest PVR of both groups.
One patient received first day postoperatively excessive
transfusion because of intra-abdominal bleeding and
hemorrhagic shock.diovascular Surgery c Volume 141, Number 4 1011
TABLE 3. Hemodynamic data
Group Pre-OP Post-OP 6 Hours post-OP
MAP (mm Hg) NO 71  3 72  2 74  2
Placebo 69  3 71  3 72  2
MPAP (mm Hg) NO 31.8  2.4 24.2  1.3y 23.5  1.5y
Placebo 32.7  2.5 24.2  1.9y 26.6  1.8y
CVP (mm Hg) NO 10.3  1.3 8.5  3.2 10.0  3.2
Placebo 10.5  1.1 9.3  1.1 10.2  0.7
PCWP (mm Hg) NO 18.2  1.7 10.4  0.9y 11.2  0.9y
Placebo 18.0  1.6 9.3  1.2y 9.1  1.0y
TPPG (mm Hg) NO 13.2  1.2 13.8  1.0 12.4  1.2
Placebo 14.8  1.3 15.0  1.3 17.6  1.5
PVR (dyn 3 s 3 cm5) NO 311  35 225  17y 205  23*
Placebo 298  26 234  23 274  30
CI (L 3 m1 3 m2) NO 1.94  0.09 2.61  0.13y 2.67  0.12y
Placebo 2.19  0.12 2.53  0.08* 2.64  0.08y
SvO2 (%) NO 71  2 76  2 74  3
Placebo 69  3 74  2 74  2
LVFRI (L 3 m1 3 m2) NO 2.55  0.14 2.58  0.09
Placebo 2.44  0.07 2.53  0.07
CI, Cardiac index; CVP, central venous pressure; LVFRI, left ventricular pump flow rate index;MAP, mean arterial pressure;MPAP, mean pulmonary artery pressure; NO, nitric
oxide; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; SvO2, mixed venous oxygen saturation; TPPG, transpulmonary pressure gradient.
Means  standard error of the mean. *P<.05. yP<.01 versus Pre-OP by 2-way RM analysis of variance; post-hoc, Holm-Sidak.
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MDISCUSSION
The main finding of our perioperative TEE study is
a marked immediate improvement of RV geometry and
function after implantation of LVAD that seems to result
from the relief of LV congestion as assessed by PCWP
and the concomitant reduction in RV afterload. iNO,
although decreasing pulmonary vascular resistance, had
no additional beneficial effect on RV geometry and
function.
Despite the high incidence of RVF after implantation of
LVAD, few previous studies have focused on its acute
effects on RV geometry and function.
In 1993, Holman et al10 described the acute worsening of
tricuspid regurgitation after LVAD implantation. They iden-
tified leftward displacement of the ventricular septum as the
presumable cause of RV dysfunction. This notion is con-
firmed by experimental data suggesting that during LVAD
support, RV function may worsen despite the reduction of
pulmonary venous pressure by unloading of LV due to an
altered systolic ventricular interaction as a result of the
change in LV/RV geometry.22
At present, intraoperative TEE is used for therapy guid-
ing during LVAD implantation.23 One of the main goals
during TEE monitoring immediately after CPB weaning
in our patients is the early recognition and therapy of se-
vere ventricular septum shift toward the left after LVAD
implantation. We recognize as an optimal balance between
RV and LV loading the middle position of the ventricular
septum in the 4C view. In addition the difference between
CVP and left atrial pressure (LAP) is monitored continu-
ously as a measure of balanced RV versus LV loading.1012 The Journal of Thoracic and Cardiovascular SurAn increasing CVP to LAP difference could be a sign of
LV unloading and RV dysfunction. Therapeutic options
for treatment of RV to LV dysbalance are additional phar-
macological support for the RV and reduction of LVAD
flow rate. With this regimen RV geometry and function im-
proved rather than worsened in the majority of patients.
Only 5 of 47 patients presented with a greater than 10%
increase in RVEDDmax. Because RV loading as assessed
by CVP was not altered, improved RVend-diastolic geom-
etry seems to result from improved systolic function due to
the marked reduction in RV afterload by LVAD implanta-
tion. PCWP and MPAP decreased by, respectively, 46%
and 25% after LVAD implantation allowing for a 29%
increase of FAC and RVEF.
More recent long-term echocardiographic evaluations
after LVAD implantation also failed to show a worsening
of RV function. Maeder et al24 reported that during
continuous-flow LVAD support, pre-existing RV dysfunc-
tion did not worsen in the intermediate term.
Lam et al25 showed that RV size, RV FAC, and TAPSE
did not consistently changewithin 6 months after LVAD im-
plantation. However, they detected marked variability in the
RV changes after implantation and demonstrated the associ-
ation between clinical improvements after LVAD implanta-
tion with the echocardiographic measures of PVR and RV
FAC.
Pronounced variability in acute RV responses to LVAD
implantation was also noted in our study. Thus, RV FAC
and EF improved predominantly in patients with severely
reduced preoperative RV function (Figure 1). The increase
in FAC or EF was not associated with the amount ofgery c April 2011
TABLE 4. Perioperative echocardiographic data
Group Pre-OP Post-OP
RVEDD 1 (mm) NO 41  2 35  1y
Placebo 39  2 35  1y
RVEDD 2 (mm) NO 42  2 39  2
Placebo 42  1 39  2
RVEDD max (mm) NO 50  2 45  2y
Placebo 48  2 44  2*
RVEDD 3 (mm) NO 81  2 72  2y
Placebo 84  2 73  2y
R/L ratio NO 0.61  0.02 0.85  0.05*
Placebo 0.58  0.02 0.95  0.12y
RVOT 1 (mm) NO 34  1 31  1
Placebo 32  1 32  1
RVOT 2 (mm) NO 26  1 25  1
Placebo 27  1 26  1
LVEDD (mm) NO 74  2 55  2y
Placebo 72  2 54  4y
RVAD (cm2) NO 23.7  1.2 20.6  1.3y
Placebo 24.5  1.2 21.1  0.9y
RVAS (cm2) NO 18.1  1.1 14.2  1.0y
Placebo 18.9  1.1 15.0  0.8y
FAC (%) NO 23.9  2.3 31.1  2.2*
Placebo 22.7  2.0 28.9  2.0*
TAPSE (mm) NO 14.5  1.4 13.0  1.1
Placebo 14.4  1.3 11.8  0.6
RVEDV (ml) NO 147  9 119  9y
Placebo 152  10 129  6y
RVESV (ml) NO 99  8 71  5y
Placebo 106  8 78  5y
RVSV (ml) NO 48  3 48  4
Placebo 46  4 51  3
RVEF (%) NO 33  2 41  2*
Placebo 29  2 39  2y
FAC, Fractional area change; LVEDD, left ventricular end-diastolic diameter; NO,
nitric oxide; RVAD, right ventricular diastolic area; RVAS, right ventricular systolic
area; RVEDD, right ventricular end-diastolic diameter; RVEDV, right ventricular
end-diastolic volume; RVEF, right ventricular ejection fraction; RVESV, right
ventricular end-systolic volume; RVOT, right ventricular outflow tract; RVSV, right
ventricular stroke volume; TAPSE, tricuspidal annular plane systolic excursion.
Means  standard error of the mean *P<.05. yP<.01 by 2-way RM analysis of
variance, post-hoc, Holm-Sidak
FIGURE 1. Postoperative changes of RV function (D FAC and EF)
depend on preoperative values. Most marked improvement was seen in
patients with severely impaired preoperative function.
TABLE 5. In-hospital outcome
NO Placebo
N 24 23
Inotropic therapy index 24 (10;32) 24 (14;31)
Ventilation (h) 51 (25;334) 74 (28;605)
ICU stay (d) 17 (10;27) 15 (9;40)
RVF (%) 3 (13) 1 (4)
30-Day mortality (%) 5 (21) 3 (13)
ICU, Intensive care unit; NO, nitric oxide; RVF, right ventricular failure. Median
(25;75 percentiles) or number (%). No significant differences between groups were
detected.
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Minotropic drugs (R ¼ 0.15, P ¼ .36 for FAC and R ¼ 0.10,
P ¼ .54 for EF). A less pronounced but still significant de-
pendence on preoperative data was also detected for end-
diastolic RV geometry (RVAD change versus pre-
operative RVAD: R ¼0.43, P ¼ .003). Obviously patients
with severe preoperative RV dysfunction profited more
from RV afterload reduction by LVAD than patients with
better preserved RF function in whom the RV could better
compensate for the increased afterload.
iNO, although decreasing PVR, had no measurable effect
on RV geometry or function. By decreasing PVR, iNO
might act as a prophylactic drug that decreases RVafterload
and improves LV loading, thus moderating the detrimental
effect of altered ventricular interaction on the RV. De-
creased pulmonary artery pressure and improved pumpThe Journal of Thoracic and Carflow rate during postoperative NO administration after iso-
lated LVAD implantation have been described previously.15
In this study, however, only patients with increased PVR
during weaning from cardiopulmonary bypass were in-
cluded. Thus a patient subgroup was selected that may profit
most from pulmonary vasodilator therapy. In the presentdiovascular Surgery c Volume 141, Number 4 1013
Perioperative Management Kukucka et al
P
Mstudy, only elective patients without acute decompensation
of chronic heart failure, but with increased preoperative
PVR were included irrespective of the hemodynamic sce-
nario during weaning. Thus the patients in the present study
were probably less severely diseased than patients in previ-
ous studies, which showed a benefit of iNO.15 In addition,
decreased PVR does not necessarily improve RV geometry
and function that were not assessed in this previous study.
Also the marked reduction in RV afterload by LVAD itself
together with the postoperative regimen of limiting the sep-
tal shift to the left by adjusting the inotropic therapy and the
LVAD flow rate may have masked potentially beneficial ef-
fects of iNO.
In accordance with the improvement of RV function seen
in the majority of patients the incidence of RV failure was
very low in our patient cohort (4 of 47). This may be due
to our stringent selection criteria to schedule primary
BiVAD implantation for patients with severe preoperative
RV dilatation, tricuspid regurgitation, and markedly re-
duced RV function.8CONCLUSIONS
In patients preselected for LVAD therapy, RV geometry
and function improve markedly immediately after LVAD
implantation, due to the unloading of the LV and the con-
comitant reduction of RV afterload. Detection of excessive
LV unloading and distortion of normal ventricular interac-
tion by TEE and its consecutive correction by pharmacolog-
ical support and adjustment of the LVAD flow rate may be
pivotal for the preservation of RV function and geometry in
these patients. The use of iNO should be reserved for those
patients who are most likely to benefit. This may include pa-
tients with high pulmonary artery pressure or low pump
flow rate during weaning from cardiopulmonary bypass.References
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